Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial
Xue Yu, Tianshu Chu, Jiankang Hu, Wei Gou, Ning Zhang, Juan Li, Jing Yu, Ran Li, Rongbin Li, Long Qian, Xinwang Duan, Lihua Duan, Xu Zhang, Yuling Lian, Yi Li, Chuang Qi, Dongzhe Huang, Hejian Zou
Abstract
< 0.0001). Efficacy was consistent across subgroups. Treatment-emergent adverse events occurred in 71.2% of Firsekibart-treated patients and 69.9% of those receiving CB. In conclusion, Firsekibart is effective and well tolerated for acute gout flares in patients unsuitable for standard therapy, demonstrating non-inferiority in rapid pain relief and significant superiority in preventing flare compared with CB.
Topics & Concepts
MedicineRandomized controlled trialBetamethasoneGoutInternal medicinePhysical therapyGout, Hyperuricemia, Uric AcidVeterinary medicine and infectious diseasesLiver Disease and Transplantation